Cassava is stopping all development of simufilam in Alzheimer’s disease. Image credit: Shutterstock / Mikadun. Cassava Sciences has officially stopped the development of its investigational drug ...

Cassava Technologies has tapped Nvidia to build Africa’s first artificial intelligence "factory". Cassava Technologies, founded by Zimbabwean telecommunications tycoon Strive Masiyiwa, has tapped ...

Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show benefit in a second Phase III trial. The company is ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era defined by controversy and failed clinical trials. The company reported the ...

Cassava Technologies has announced plans to construct Africa’s first AI factory, a state-of-the-art data center facility equipped with NVIDIA’s advanced AI computing technology. The initiative aims to ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava Technologies has announced plans to build Africa’s first “AI Factory” — a high-performance, AI-enabled data center powered by NVIDIA’s advanced computing technology. At the ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease Simufilam continued to ...

Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies ...